Adicet Bio, Inc.
Adicet Bio, Inc. (ACET): 5 pipeline candidates · 1 upcoming catalyst · ~19 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
18.9 months
D/E 0.21 · 12% dilution
Lead: Phase 1
5 candidates
1 upcoming, next in ~242d
3 buys · 4 sells (180d)
A transparent, data-derived signal for Adicet Bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$75.7M
Cash
$39.1M
Quarterly Burn
$21.5M
Runway
18.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| ADI-001 | Phase 1 |
| adi-212 | Phase 1 |
| ADI-270 | Phase 1 |
| prula-cel | Phase 1 |
| prulacabtagene leucel (prula-cel | Phase 1 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$41.7M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 1,182,624 | $8.1M |
| orbimed advisors llc | 1,027,944 | $7.0M |
| vanguard capital management llc | 673,048 | $4.6M |
| franklin resources inc | 626,571 | $4.3M |
| citadel advisors llc | 381,823 | $2.6M |
| adage capital partners gp, l.l.c. | 274,375 | $1.9M |
| prosight management, lp | 250,244 | $1.7M |
| renaissance technologies llc | 232,591 | $1.6M |
| alyeska investment group, l.p. | 203,799 | $1.4M |
| carlyle group inc. | 184,295 | $1.3M |
Showing top 10 of 46 institutional holders of Adicet Bio, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Adicet Bio, Inc.'s pipeline?
Adicet Bio, Inc. (ACET) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Adicet Bio, Inc.'s lead drug candidate?
Adicet Bio, Inc.'s most advanced tracked candidate is ADI-001 (Phase 1) for Lupus Nephritis; Lymphoma, Follicular.
What is Adicet Bio, Inc.'s next catalyst?
Adicet Bio, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Ritux" — expected February 15, 2027.
What is Adicet Bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Adicet Bio, Inc. has approximately 18.9 months of cash runway.
What is Adicet Bio, Inc.'s market capitalization?
Adicet Bio, Inc.'s market capitalization is approximately $75.7M.
Get the full picture on Adicet Bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.